Freiburg Im Breisgau

• A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory col … Ended
  2023-509771-17-00 10 2024-06-04 Metastatic Colorectal cancer (mCRC)
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended
  2023-506655-19-00 4 2024-05-16 Ulcerative Colitis (UC)
• A phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metast … Ended
  2023-505257-40-00 9 2024-04-17 metastatic esophagogastric adenocarcinoma (Stage IV)
• A Safety, Tolerability and Efficacy Study of VRDN-001 in Persons with Chronic Thyroid Eye Disease (TED) Ended
  2023-507217-10-00 5 2024-04-12 Thyroid eye disease
• A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended
  2023-506707-25-00 5 2024-04-09 Choroidal neovascularization secondary to pathologic myopia
• Ph 3b, BIC/FTC/TAF to DTG/3TC FDC, 96 Week switch, efficacy, safety, and tolerability study in ART-experienced older adults living with HIV … Ended
  2022-503137-66-00 5 2023-11-29 Human immunodeficiency virus (HIV)
• A study to test whether BI 765845 helps people who have had a heart attack Ended
  2022-502788-39-00 4 2023-11-27 acute myocardial infarction
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended
  2022-500777-14-00 4 2023-11-06 Atopic Dermatitis
• A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) Ended
  2022-502227-22-00 4 2023-10-25 Autoimmune disease
• A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-S … Ended
  2023-505558-16-00 5 2023-10-24 Atopic Dermatitis
• Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE) Ended
  2022-501523-24-00 4 2023-10-12 Cutaneous Lupus Erythematosus (CLE)
• Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension Ended
  2023-504534-21-00 5 2023-10-09 18 driven monogenic autoinflammatory conditions: NLRC4 mutation and XI
• A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Ep … Ended
  2022-503067-15-00 5 2023-10-02 Tuberous Sclerosis Complex (TSC) related epilepsy
• A study to compare the effects and safety of gadoquatrane with an already used available contrast agent for MRI tests in people with any kno … Ended
  2022-501885-24-00 5 2023-09-20 Contrast enhancement in magnetic resonance imaging for assessment of n
• A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a … Ended
  2022-501895-25-00 5 2023-09-13 Polymyalgia Rheumatica
• A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced … Ended
  2022-502174-16-00 5 2023-09-13 Macular edema secondary to retinal vein occlusion
• SEER-3: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of … Ended
  2022-502697-16-00 5 2023-08-29 Neurotrophic Keratopathy
• Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended
  2022-502000-73-00 5 2023-08-11 Focal Onset Seizures
• A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC) Ended
  2023-507027-37-00 3 2023-07-20 Primary Sclerosing Cholangitis (PSC)
• A STUDY TO INVESTIGATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERED INTRAVITREALLY IN PATIENTS WIT … Ended
  2022-501794-39-00 5 2023-06-28 Uveitic Macular Edema
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended
  2022-500536-11-01 5 2023-06-08 Moderately to severely active ulcerative colitis
• A study to see how well CVGBM vaccine works at different doses and how safe it is in patients who had surgery for glioblastoma or astrocytom … Ended
  2022-501423-25-00 7 2023-05-05 Surgically Resected Glioblastoma (GBM) or Astrocytoma with a Molecular
• A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is Ended
  2022-501362-22-00 10 2023-04-18 Psoriatic Arthritis

Showing 409–432 of 485 trials